$GDRX


After A 30% Surge On The $NVO News, Is The Story Just Beginning?
Novo Nordisk partners with GoodRx for $499 monthly Ozempic, Wegovy

Novo Nordisk (NVO) has entered into a collaboration with GoodRx (NASDAQ:GDRX) to supply type 2 diabetes and weight loss meds Ozempic and Wegovy for $499 a month for self-pay customers.

GoodRx has surged ~29% in early morning trading Monday.

Under the arrangement, GoodRx customers who self-pay can use their prescription savings card at more than 70,000 pharmacies across the U.S. to get either of the drugs with a prescription at the discounted price.

GoodRx said that over the last year, nearly 17M people visited its website for savings and information on GLP-1 medications, such as Ozempic and Wegovy, which both contain the active ingredient semaglutide. That's a 22% increase from the previous year.
IN-3.72%
MORE-1.31%
post-image
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)